For development of an effective gene therapy for the HAND treatment, it is essential to have an hDAT mutant which does not significantly bind with Tat so that Tat will not significantly affect the dopamine uptake activity of the hDAT mutant. Here, TAT is linked to HIV-associated neurocognitive disorder.